Eptinezumab for teens with chronic migraine
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests eptinezumab, a preventive medicine, to reduce headache frequency in teens with chronic migraine. It may help your teen if they have frequent migraine days despite usual care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your teen has migraine (with or without aura) and a diagnosis of chronic migraine for at least 6 months before screening
- During the 4-week screening period, your teen completes the headache eDiary on at least 23 of 28 days
- During the same 4 weeks, your teen has 15–26 headache days, including 8–26 days that are migraine days
- Your teen has never taken eptinezumab before in this study
- Your teen has not had certain migraine antibody treatments (including any CGRP antibody or monoclonal antibody) within the last 6 months
- Your teen does not have “complicated” or unusual migraine types (and not other specific headache disorders like cluster or tension-type)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests eptinezumab to reduce migraine attacks in children who have episodic migraine (not daily chronic migraine). It may help by lowering the number of headache days and migraine days over time. You must complete a headache diary during screening to be considered.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This real-world study looks at how well eptinezumab (an antibody medicine for migraine prevention) works for people with frequent episodic or chronic migraine as they get usual care. You may be asked to share health information and treatment details to see what helps most in everyday life.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
This trial tests if a medication called eptinezumab can help stop headaches that start after a head injury. If you have new headaches since your injury and they happen within the first 8 weeks, this study may offer early treatment.
Hear when a new Chronic Migraine in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.